Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A18-14
Last updated

Report documents

  1. Extract of dossier assessment

    Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 343 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 343 kB, EN, not accessible)

  2. Dossier assessment

    Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 595 kB, DE, not accessible
    Download file : Dossier assessment (PDF document, 595 kB, DE, not accessible)

Dossier assessment

Indication:

Patients with active psoriatic arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies

Result of dossier assessment:

Patients who have responded inadequately to treatment with a conventional DMARD or a bDMARD: added benefit not proven due to lack of data. If first bDMARD treatment is indicated: hint of minor added benefit

Additional information

Federal Joint Committee (G-BA)

2018-08-16 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A18-14
Commission
Commission awarded on 20.02.2018 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Muscles, bones and joints
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Addendum

    Ixekizumab (psoriatic arthritis) - Addendum to Commission A18-14

    Project no.
    A18-47
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-07
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-65
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-66
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Ixekizumab (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-121
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Ixekizumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-120
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page